alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 651–675 of 694 studies in Risk factors · free to read (page 27 of 28) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

What “Risk factors” covers

Risk factors — Conditions, exposures and habits linked to a higher or lower chance of dementia, and how strong each link is.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Discrimination, Stress, and Health Across the Life Course

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Innovation in Aging 2025-12-01

These findings highlight the variability in the cumulative patterning of racial discrimination and stress among midlife and older Black adults, providing insights into how these factors impact health outcomes in middle to late life. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cross-boundary Cancer Studies at the University of Tokyo: Food and Cancer

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Japanese Journal of Clinical Oncology 2014-02-01

He has been actively delivering lectures on the prevention of diseases associated with adult lifestyle habits and the preservation of the global environment via ‘shokuiku,’ or food education. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Strengths and support of older people affected by precarity in South Louisiana

✓ Peer-reviewed alzhub usefulness score 26 out of 100. International Journal of Older People Nursing 2019-03-12

The findings demonstrate five central negative conditions of precarity that older people had to manage: (a) loss and discontinuity of home-based healthcare services, (b) stress after loss or disruption of social support, (c) problems of poverty, (d) cognitive impairment and declining health and (e) stress of eviction. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Spatial Reorganization and Governance Synergy: Innovative Practices for Strengthening County-Level Wealth-Creating Industries—A Case Study of the Huameidani Area

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Nurture 2026-05-21

In 2026, the beginning of the 15th Five-Year Plan, the Central No. 1 Document emphasized the cultivation and expansion of county-level wealth-creating industries as the core approach to ensuring stable income growth for farmers. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Spatial Bayesian Small Area Estimation of Stunting Prevalence at the Subdistrict Level

✓ Peer-reviewed alzhub usefulness score 26 out of 100. InPrime: Indonesian Journal of Pure and Applied Mathematics 2025-10-17

Compared to direct estimation, the HB SAE model reduced the number of sub-districts with Relative Standard Errors (RSE) above 25% from 55 to 44, achieving lower Mean Squared Error (MSE) values and more stable estimates. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer Europe Publication Highlights Inequalities in Access to Dementia Care and Treatment Across Europe

✓ Peer-reviewed alzhub usefulness score 24 out of 100. European Neurological Review 2017

The objective of a new report, ‘European Dementia Monitor 2017: comparing and benchmarking national dementia strategies and policies’, is to provide a benchmark of national dementia policies in order to compare the responses of European countries to the dementia challenge in different domains. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events